Overview

A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects

Status:
Completed

Trial end date:
2014-04-01

Target enrollment:

Participant gender:

Summary

To evaluate the pharmacokinetic (PK) characteristics of lurasidone after single oral administration of different doses in healthy Chinese subjects. To evaluate the safety and tolerability of lurasidone after single oral administration of different doses in healthy Chinese subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Sumitomo Pharmaceutical (Suzhou) Co., Ltd.

Collaborator:

Xuhui Central Hospital, Shanghai

Treatments:

Lurasidone Hydrochloride